Abstract
Normal hematopoiesis is maintained by dynamic interactions between hematopoietic cells and the bone marrow microenvironment. In hematological malignancies, there are reciprocal interactions between leukemic cells and cells of the bone marrow microenvironment such as stroma, osteoblasts and endothelium. In this review, we will discuss the influence of the microenvironment on the evolution of the leukemic phenotype. We propose that specific niches within the bone marrow microenvironment may provide a sanctuary for subpopulations of leukemic cells to evade chemotherapyinduced death and allow acquisition of a drug-resistant phenotype. We will also discuss recent studies that suggest novel therapeutic interventions targeting the microenvironment/leukemia interaction. Focus on this stroma-leukemia crosstalk may result in the development of strategies that alleviate the acquisition of a chemoresistant phenotype and enhance the efficacy of therapies in hematological malignancies.
Keywords: Leukemia, microenvironment, chemoresistance, angiogenesis
Current Drug Targets
Title: Targeting the Leukemia Microenvironment
Volume: 8 Issue: 6
Author(s): Marina Konopleva and Michael Andreeff
Affiliation:
Keywords: Leukemia, microenvironment, chemoresistance, angiogenesis
Abstract: Normal hematopoiesis is maintained by dynamic interactions between hematopoietic cells and the bone marrow microenvironment. In hematological malignancies, there are reciprocal interactions between leukemic cells and cells of the bone marrow microenvironment such as stroma, osteoblasts and endothelium. In this review, we will discuss the influence of the microenvironment on the evolution of the leukemic phenotype. We propose that specific niches within the bone marrow microenvironment may provide a sanctuary for subpopulations of leukemic cells to evade chemotherapyinduced death and allow acquisition of a drug-resistant phenotype. We will also discuss recent studies that suggest novel therapeutic interventions targeting the microenvironment/leukemia interaction. Focus on this stroma-leukemia crosstalk may result in the development of strategies that alleviate the acquisition of a chemoresistant phenotype and enhance the efficacy of therapies in hematological malignancies.
Export Options
About this article
Cite this article as:
Konopleva Marina and Andreeff Michael, Targeting the Leukemia Microenvironment, Current Drug Targets 2007; 8 (6) . https://dx.doi.org/10.2174/138945007780830827
DOI https://dx.doi.org/10.2174/138945007780830827 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma
Current Cancer Drug Targets Synthesis, Characterization and Evaluation of Cytotoxicity of New Aminophosphonic Acid Diesters in Human Leukemia Cells
Letters in Drug Design & Discovery Diffuse Large B-Cell Lymphoma Presenting as an Anterior Chest Wall Mass: A Case Report and Literature Review
Current Respiratory Medicine Reviews Molecular Imaging Aided Improvement in Drug Discovery and Development
Current Biotechnology Angiogenesis in Chronic Lymphocytic Leukemia
Current Angiogenesis (Discontinued) Immunotherapeutic and Immunoregulatory Drugs in Haematologic Malignancies
Current Topics in Medicinal Chemistry Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Current Pharmaceutical Design Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus- Host Disease After Allogeneic Hematopoietic Cell Transplantation
Current Stem Cell Research & Therapy Pernicious Anemia: Fundamental and Practical Aspects in Diagnosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Physiology of Immune System: Regulation of Stem Cell Survival
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Editorial
Current Pharmaceutical Biotechnology Disruption of Cell Death Signaling in Cancer: Impact on Disease Prognosis and Response to Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Role of Inflammation in the Development of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Microgravity Alters Cancer Growth and Progression
Current Cancer Drug Targets Recent Progress in the Development of Histone Deacetylase Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung Cancer
Current Medicinal Chemistry A Novel Quinoline Based Second-generation mTOR Inhibitor that Induces Apoptosis and Disrupts PI3K-Akt-mTOR Signaling in Human Leukemia HL-60 Cells
Anti-Cancer Agents in Medicinal Chemistry Immunotherapy Approaches in Cancer Treatment
Current Pharmaceutical Biotechnology De Novo DNMTs and DNA Methylation: Novel Insights into Disease Pathogenesis and Therapy from Epigenomics
Current Pharmaceutical Design Low Activity of Plasminogen Activator: A Common Feature of Non- Iatrogenic Comorbidities of Schizophrenia
CNS & Neurological Disorders - Drug Targets